Ken Griffin Ikena Oncology, Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 158,215 shares of IKNA stock, worth $218,336. This represents 0.0% of its overall portfolio holdings.

Number of Shares

158,215

Previous 79,687 98.55%

Holding current value

$218,336

Previous $101,000 109.9%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.03 - $1.47 $80,883 - $115,436	78,528 Added 98.55%	158,215 $212,000
Q1 2025 May 15, 2025	SELL	$1.28 - $1.69 $871 - $1,150	-681 Reduced 0.85%	79,687 $101,000
Q4 2024 Feb 14, 2025	SELL	$1.53 - $1.76 $129,509 - $148,978	-84,647 Reduced 51.3%	80,368 $131,000
Q3 2024 Nov 14, 2024	SELL	$1.6 - $1.85 $127,480 - $147,398	-79,675 Reduced 32.56%	165,015 $285,000
Q2 2024 Aug 14, 2024	BUY	$1.24 - $1.82 $106,237 - $155,928	85,675 Added 53.88%	244,690 $403,000
Q1 2024 May 15, 2024	SELL	$1.27 - $2.0 $24,335 - $38,324	-19,162 Reduced 10.75%	159,015 $225,000
Q4 2023 Feb 14, 2024	SELL	$1.33 - $4.4 $37,984 - $125,664	-28,560 Reduced 13.81%	178,177 $351,000
Q3 2023 Nov 14, 2023	BUY	$4.09 - $6.43 $689,639 - $1.08 Million	168,616 Added 442.32%	206,737 $895,000
Q2 2023 Aug 14, 2023	SELL	$3.5 - $7.31 $496,916 - $1.04 Million	-141,976 Reduced 78.83%	38,121 $250,000
Q1 2023 May 15, 2023	SELL	$2.62 - $4.97 $5.17 Million - $9.82 Million	-1,975,037 Reduced 91.64%	180,097 $621,000
Q4 2022 Feb 14, 2023	SELL	$2.0 - $3.7 $6,690 - $12,376	-3,345 Reduced 0.15%	2,155,134 $5.73 Million
Q3 2022 Nov 14, 2022	BUY	$3.46 - $6.0 $110,989 - $192,468	32,078 Added 1.51%	2,158,479 $7.66 Million

Others Institutions Holding IKNA

# of Institutions

Shares Held

33.6M

Call Options Held

Put Options Held

View Full List

About Ikena Oncology, Inc.

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $50M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

More about IKNA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account